Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection

1 Jan 2020

Abstract excerpt

Rationale: Epstein-Barr virus (EBV) is the causative pathogen for infectious mononucleosis and many kinds of malignancies including several lymphomas such as Hodgkin's lymphoma, Burkitt's lymphoma and NK/T cell lymphoma as well as carcinomas such as nasopharyngeal carcinoma (NPC) and EBV-associated gastric carcinoma (EBV-GC). However, to date no available prophylactic vaccine was launched to the market for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Plant Virus Research Studies
Share to Polyomavirus and related diseases
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32483413
DOI: 10.7150/thno.42494

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infectionPMID 32483413Read ↗

A Virus-Like Particle-Based Epstein-Barr Virus VaccineSemantic proximity Read ↗

Contriving multiepitope subunit vaccine by exploiting structural and nonstructural viral proteins to prevent Epstein–Barr virus‐associated malignancySemantic proximity Read ↗

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target AntigensSemantic proximity Read ↗

A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infectionSemantic proximity Read ↗

Developments in virus-like particle-based vaccines for infectious diseases and cancerSemantic proximity Read ↗

Construction of Epstein-Bar virus cocktail peptide fused with Fcγ of IgG: as a potential delivery system for vaccine developmentSemantic proximity Read ↗

The coming of age of virus-like particle vaccinesSemantic proximity Read ↗

Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancerSemantic proximity Read ↗

Virus‐like particles as powerful vaccination strategy against human virusesSemantic proximity Read ↗

Advances and challenges in enveloped virus-like particle (VLP)-based vaccinesSemantic proximity Read ↗

Recent Progress on the Versatility of Virus-Like ParticlesSemantic proximity Read ↗

Identification of a Novel Neutralizing and Two Non-Neutralizing Epitopes on Epstein-Barr Virus gp350 ProteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.